Phase 2/3 Study of KPL-387 in Recurrent Pericarditis

Recruiting now · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Pericarditis, Pericarditis Acute, Recurrent Pericarditis

In brief

This study is being done to demonstrate whether KPL-387 is an effective and safe treatment for recurrent pericarditis.

Key facts

Study ID

NCT07010159

Run by

Kiniksa Pharmaceuticals International, plc

People needed

165

Starts

2025-07-25

Expected to finish

2029-12-31

Last updated by the study team

2026-06-08

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Investigational Site 023 — Norfolk, Virginia, United States (enrolling)
• Investigational Site 030 — Los Angeles, California, United States (enrolling)
• Investigational Site 053 — Phoenix, Arizona, United States (enrolling)
• Investigational Site 018 — Gilbert, Arizona, United States (enrolling)
• Investigational Site 058 — Ventura, California, United States (enrolling)
• Investigational Site 016 — Westminster, Colorado, United States (enrolling)
• Investigational Site 008 — San Francisco, California, United States (enrolling)
• Investigational Site 004 — Chicago, Illinois, United States (enrolling)
• Investigational Site 014 — Indianapolis, Indiana, United States (enrolling)
• Investigational Site 044 — Santa Monica, California, United States (enrolling)
• Investigational Site 043 — Baltimore, Maryland, United States (enrolling)
• Investigational Site 054 — Boston, Massachusetts, United States (enrolling)
• Investigational Site 055 — Minneapolis, Minnesota, United States (enrolling)
• Investigational Site 012 — Rochester, Minnesota, United States (enrolling)
• Investigational Site 050 — Kansas City, Missouri, United States (enrolling)
• Investigational Site 046 — Kansas City, Missouri, United States (enrolling)
• Investigational Site 015 — New York, New York, United States (enrolling)
• Investigational Site 022 — New York, New York, United States (enrolling)
• Investigational Site 009 — Cincinnati, Ohio, United States (enrolling)
• Investigational Site 003 — Cleveland, Ohio, United States (enrolling)
• Investigational Site 005 — Austin, Texas, United States (enrolling)
• Investigational Site 013 — Houston, Texas, United States (enrolling)
• Investigational Site 042 — Burlington, Vermont, United States (enrolling)
• Investigational Site 006 — Charlottesville, Virginia, United States (enrolling)
• Investigational Site 045 — Richmond, Virginia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.